Delving into the Latest Updates on Zhengda Pharmaceutical (Guangzhou) Co., Ltd. with Synapse

Overview

Tags

Endocrinology and Metabolic Disease

Respiratory Diseases

Digestive System Disorders

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Bispecific antibody	1

Top 5 Target	Count

GIPR x GLP-1R	1

SAD：主要目的评估CPX101单次给药在健康参与者中的安全性和耐受性。次要目的评估CPX101单次给药在健康参与者中的药代动力学（PK）特征。探索性目的评价CPX101单次给药在健康参与者中的免疫原性。 MAD：主要目的评估CPX101多次给药在超重和肥胖患者中的安全性和耐受性。次要目的评估CPX101多次给药在超重和肥胖患者中的初步疗效。评估CPX101多次给药在超重和肥胖患者中的PK特征。评估CPX101多次给药在超重和肥胖患者中的免疫原性。

[Translation]

SAD: Primary objective To evaluate the safety and tolerability of a single dose of CPX101 in healthy participants. Secondary objective To evaluate the pharmacokinetic (PK) characteristics of a single dose of CPX101 in healthy participants. Exploratory objective To evaluate the immunogenicity of a single dose of CPX101 in healthy participants. MAD: Primary objective To evaluate the safety and tolerability of multiple doses of CPX101 in overweight and obese patients. Secondary objectives To evaluate the preliminary efficacy of multiple doses of CPX101 in overweight and obese patients. To evaluate the PK characteristics of multiple doses of CPX101 in overweight and obese patients. To evaluate the immunogenicity of multiple doses of CPX101 in overweight and obese patients.

Start Date-

Sponsor / Collaborator

Zhengda Pharmaceutical (Guangzhou) Co., Ltd.

NCT06545162 / Not yet recruitingPhase 1

A Randomized, Double-blind, Placebo-controlled, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of CPX101 in Healthy Volunteers and Overweight or Obese Patients With Multiple Doses

This randomized, double-blind, placebo-controlled Phase I clinical study was designed to evaluate the tolerability and safety, PK profile, immunogenicity of CPX101 in a single dose in healthy participants and multiple doses in overweight and obese patients, and to initially explore the efficacy of multiple doses in weight loss. The study was divided into two parts: single administration and dose escalation (SAD) and multiple administration and dose escalation (MAD).

Start Date01 Sep 2024

Sponsor / Collaborator

Zhengda Pharmaceutical (Guangzhou) Co., Ltd.

NCT06532578 / RecruitingPhase 2

A Randomized, Double-blind, Placebo-controlled, Parallel-group Multicenter Trial to Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus

The study is designed to evaluate the preliminary efficacy, safety, population PK profile, and immunogenicity of CPX101 in subjects with obesity or overweight with weight related comorbidities but without diabetes mellitus.

Start Date13 Aug 2024

Sponsor / Collaborator

Zhengda Pharmaceutical (Guangzhou) Co., Ltd.

100 Clinical Results associated with Zhengda Pharmaceutical (Guangzhou) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhengda Pharmaceutical (Guangzhou) Co., Ltd.

Login to view more data

100 Deals associated with Zhengda Pharmaceutical (Guangzhou) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhengda Pharmaceutical (Guangzhou) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 07 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2 Clinical

1

Login to view more data